TSE:4502Pharmaceuticals
Takeda Pharmaceutical (TSE:4502): Reassessing Valuation After Positive 52-Week Rusfertide Phase 3 Data
Takeda Pharmaceutical (TSE:4502) is back in focus after presenting new 52 week Phase 3 VERIFY data for rusfertide in polycythemia vera at the American Society of Hematology meeting, underscoring durable efficacy and a consistent safety profile.
See our latest analysis for Takeda Pharmaceutical.
The latest rusfertide update lands against a backdrop of steady gains, with Takeda Pharmaceutical’s share price up over the year and a solid multi year total shareholder return suggesting gradually...